Vaxcyte Completes Enrollment for Opus-1 & Opus-2 Phase 3 VAX-31 Trials, Advancing Lead Vaccine
Summary
Vaxcyte has announced the completion of enrollment for its Opus-1 and Opus-2 Phase 3 clinical trials evaluating VAX-31 for the prevention of invasive pneumococcal disease and pneumonia in adults. This significant milestone follows the positive Phase 1/2 adult clinical trial data for VAX-31 published earlier this month, reinforcing the company's rapid advancement of its lead vaccine candidate. Completing enrollment is a critical de-risking step in the drug development process, indicating that the trials are progressing as planned and moving the company closer to key data readouts. Traders will now focus on the timelines for these readouts, which will be crucial for assessing VAX-31's efficacy and safety profile. The company also noted Opus-3 Phase 3 results are expected in the first half of 2027.
At the time of this announcement, PCVX was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $27.66 to $76.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.